Effect of Netazepide, a Gastrin/CCK2 Receptor Antagonist, on Gastric Acid Secretion and Rabeprazole-induced Hypergastrinaemia in Healthy Subjects

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2014 Oct 23

PMID 25335860

Citations 10

Authors

Malcolm Boyce

Sally Dowen

Gillian Turnbull

Frans van den Berg

Chun-Mei Zhao

Duan Chen

James Black

Affiliations

Soon will be listed here.

Abstract

Aims: To compare gastric acid suppression by netazepide, a gastrin/CCK2 receptor antagonist, with that by a proton pump inhibitor (PPI), and to determine if netazepide can prevent the trophic effects of PPI-induced hypergastrinaemia.

Methods: Thirty healthy subjects completed a double-blind, randomized, parallel group trial of oral netazepide and rabeprazole, alone and combined, once daily for 6 weeks. Primary end points were: basal and pentagastrin-stimulated gastric acid and 24 h circulating gastrin and chromogranin A (CgA) at baseline, start and end of treatment, gastric biopsies at baseline and end of treatment and basal and pentagastrin-stimulated gastric acid and dyspepsia questionnaire after treatment withdrawal.

Results: All treatments similarly inhibited pentagastrin-stimulated gastric acid secretion. All treatments increased serum gastrin, but the combination and rabeprazole did so more than netazepide alone. The combination also reduced basal acid secretion. Rabeprazole increased plasma CgA, whereas netazepide and the combination reduced it. None of the biopsies showed enterochromaffin-like (ECL) cell hyperplasia. Withdrawal of treatments led neither to rebound hyperacidity nor dyspepsia.

Conclusions: Netazepide suppressed pentagastrin-stimulated gastric acid secretion as effectively as did rabeprazole. The reduction in basal acid secretion and greater increase in serum gastrin by the combination is consistent with more effective acid suppression. Despite our failure to show rabeprazole-induced ECL cell hyperplasia and rebound hyperacidity, the increase in plasma CgA after rabeprazole is consistent with a trophic effect on ECL cells, which netazepide prevented. Thus, netazepide is a potential treatment for the trophic effects of hypergastrinaemia and, with or without a PPI, is a potential treatment for acid-related conditions.

Citing Articles

Hesperidin enhances broiler growth performance by augmenting gastric acid secretion via the proton pump pathway.

Li Y, An M, Wan S, Li Y, Du Y, Zhao Y Poult Sci. 2025; 104(2):104781.

PMID: 39778363 PMC: 11761918. DOI: 10.1016/j.psj.2025.104781.

The state of the art in secondary pharmacology and its impact on the safety of new medicines.

Brennan R, Jenkinson S, Brown A, Delaunois A, Dumotier B, Pannirselvam M Nat Rev Drug Discov. 2024; 23(7):525-545.

PMID: 38773351 DOI: 10.1038/s41573-024-00942-3.

Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.

Bernard A, Mroue M, Bourthoumieu S, Boyce M, Richard L, Sturtz F Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399359 PMC: 10892341. DOI: 10.3390/ph17020144.

Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology.

Chen D, Hagen S, Boyce M, Zhao C J Neuroendocrinol. 2023; 35(11):e13305.

PMID: 37317882 PMC: 10656367. DOI: 10.1111/jne.13305.

Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice.

Bernard A, Danigo A, Mroue M, Rovini A, Richard L, Nizou A Pharmaceutics. 2022; 14(12).

PMID: 36559317 PMC: 9788598. DOI: 10.3390/pharmaceutics14122823.

References

Takaishi S, Shibata W, Tomita H, Jin G, Yang X, Ericksen R . In vivo analysis of mouse gastrin gene regulation in enhanced GFP-BAC transgenic mice. Am J Physiol Gastrointest Liver Physiol. 2010; 300(2):G334-44. PMC: 3043646. DOI: 10.1152/ajpgi.00134.2010. View

Hunfeld N, Geus W, Kuipers E . Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007; 25(1):39-46. DOI: 10.1111/j.1365-2036.2006.03171.x. View

Sanduleanu S, de Bruine A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W . Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest. 2001; 31(9):802-11. DOI: 10.1046/j.1365-2362.2001.00890.x. View

Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B . Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol. 2005; 17(5):559-66. DOI: 10.1097/00042737-200505000-00013. View

Kidd M, Siddique Z, Drozdov I, Gustafsson B, Camp R, Black J . The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept. 2010; 162(1-3):52-60. DOI: 10.1016/j.regpep.2010.01.009. View

Chen D, Zhao C, Norlen P, Bjorkqvist M, Ding X, Kitano M . Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study. Cell Tissue Res. 2000; 299(1):81-95. DOI: 10.1007/s004419900136. View

Niklasson A, Lindstrom L, Simren M, Lindberg G, Bjornsson E . Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010; 105(7):1531-7. DOI: 10.1038/ajg.2010.81. View

Qvigstad G, Falkmer S, Westre B, Waldum H . Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas"). APMIS. 2000; 107(12):1085-92. DOI: 10.1111/j.1699-0463.1999.tb01513.x. View

Konagaya T, Bernsand M, Norlen P, Hakanson R . Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats. Br J Pharmacol. 2001; 133(1):37-42. PMC: 1572754. DOI: 10.1038/sj.bjp.0704037. View

10.

Gillen D, Wirz A, Ardill J, McColl K . Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999; 116(2):239-47. DOI: 10.1016/s0016-5085(99)70118-6. View

11.

Schubert M, Peura D . Control of gastric acid secretion in health and disease. Gastroenterology. 2008; 134(7):1842-60. DOI: 10.1053/j.gastro.2008.05.021. View

12.

Bonapace E, Fisher R, Parkman H . Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?. Dig Dis Sci. 2000; 45(1):34-9. DOI: 10.1023/a:1005496907686. View

13.

Bjorkqvist M, Dornonville de la Cour C, Zhao C, Hakanson R, Norlen P . Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats. Regul Pept. 2002; 108(2-3):73-82. DOI: 10.1016/s0167-0115(02)00111-8. View

14.

Waldum H, Arnestad J, Brenna E, Eide I, Syversen U, Sandvik A . Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996; 39(5):649-53. PMC: 1383386. DOI: 10.1136/gut.39.5.649. View

15.

Peghini P, Annibale B, Azzoni C, Milione M, Corleto V, Gibril F . Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002; 123(1):68-85. DOI: 10.1053/gast.2002.34231. View

16.

Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S . Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther. 2012; 36(2):181-9. DOI: 10.1111/j.1365-2036.2012.05143.x. View

17.

Hakanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F . Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology. 1993; 105(1):15-21. DOI: 10.1016/0016-5085(93)90005-w. View

18.

Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T . Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2006; 61(3):315-20. PMC: 1885016. DOI: 10.1111/j.1365-2125.2005.02566.x. View

19.

Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y . YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther. 1997; 11(1):113-20. DOI: 10.1046/j.1365-2036.1997.110281000.x. View

20.

El-Omar E, Oien K, Gillen D, Wirz A, Dahill S, Williams C . Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997; 113(1):15-24. DOI: 10.1016/s0016-5085(97)70075-1. View